Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine.

Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, Conner TA, Chertow GM, Bhatt DL, Shunk K, Parikh CR, McFalls EO, Brophy M, Ferguson R, Wu H, Androsenko M, Myles J, Kaufman J, Palevsky PM; PRESERVE Trial Group.

N Engl J Med. 2018 Feb 15;378(7):603-614. doi: 10.1056/NEJMoa1710933. Epub 2017 Nov 12.

2.

Correlates of skin-related quality of life (QoL) in those with multiple keratinocyte carcinomas (KCs): A cross-sectional study.

Siegel JA, Chren MM, Weinstock MA; Department of Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Group.

J Am Acad Dermatol. 2016 Sep;75(3):639-642. doi: 10.1016/j.jaad.2016.05.008. No abstract available.

PMID:
27543222
3.

Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.

Pomerantz H, Hogan D, Eilers D, Swetter SM, Chen SC, Jacob SE, Warshaw EM, Stricklin G, Dellavalle RP, Sidhu-Malik N, Konnikov N, Werth VP, Keri J, Lew R, Weinstock MA; Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial Group.

JAMA Dermatol. 2015 Sep;151(9):952-60. doi: 10.1001/jamadermatol.2015.0502.

PMID:
25950503
4.

Neuropsychological changes following deep brain stimulation surgery for Parkinson's disease: comparisons of treatment at pallidal and subthalamic targets versus best medical therapy.

Rothlind JC, York MK, Carlson K, Luo P, Marks WJ Jr, Weaver FM, Stern M, Follett K, Reda D; CSP-468 Study Group.

J Neurol Neurosurg Psychiatry. 2015 Jun;86(6):622-9. doi: 10.1136/jnnp-2014-308119. Epub 2014 Sep 2.

PMID:
25185211
5.

Measuring the severity of topical 5-fluorouracil toxicity.

Korgavkar K, Firoz EF, Xiong M, Lew R, Marcolivio K, Burnside N, Dyer R, Weinstock MA; VAKCC Trial Group.

J Cutan Med Surg. 2014 Jul-Aug;18(4):229-35.

PMID:
25008439
6.

Predictors of local adverse effects caused by topical tretinoin cream 0ยท1% in the Veterans Affairs Topical Tretinoin Chemoprevention trial.

Pomerantz H, Weinstock MA; Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Group.

Br J Dermatol. 2014 Sep;171(3):642-5. doi: 10.1111/bjd.12987. Epub 2014 Jul 23.

PMID:
24666361
7.

Fluorouracil and other predictors of morpheaform basal cell carcinoma among high-risk patients: the Veterans Affairs Topical Tretinoin Chemoprevention Trial.

Xiong MY, Korgavkar K, Digiovanna JJ, Weinstock MA; Veterans Affairs Topical Tretinoin Chemoprevention Trial Group.

JAMA Dermatol. 2014 Mar;150(3):332-4. doi: 10.1001/jamadermatol.2013.5619. No abstract available.

PMID:
24258386
8.

Periocular actinic keratosis, keratinocyte carcinomas, and eyeglasses use.

Lee KC, Weinstock MA; Department of Veterans Affairs Topical Tretinoin Chemoprevention Trial Group.

J Am Acad Dermatol. 2013 Jul;69(1):165-7. doi: 10.1016/j.jaad.2013.02.015. No abstract available.

PMID:
23768294
9.

Therapies for active rheumatoid arthritis after methotrexate failure.

O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S, Keystone E; CSP 551 RACAT Investigators.

N Engl J Med. 2013 Jul 25;369(4):307-18. doi: 10.1056/NEJMoa1303006. Epub 2013 Jun 11.

10.

Predictors of squamous cell carcinoma in high-risk patients in the VATTC trial.

Xiong MY, Rizzo AE, Cohen TS, Dyer RK, Korgavkar K, Bingham SF, Weinstock MA; Veterans Affairs Topical Tretinoin Chemoprevention(VATTC) Trial Group.

J Invest Dermatol. 2013 Jun;133(6):1521-32. doi: 10.1038/jid.2013.35. Epub 2013 Feb 24.

11.

Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA Topical Tretinoin Chemoprevention) trial.

Dyer RK, Weinstock MA, Cohen TS, Rizzo AE, Bingham SF; VATTC Trial Group.

J Invest Dermatol. 2012 Nov;132(11):2544-51. doi: 10.1038/jid.2012.227. Epub 2012 Jul 19.

12.

Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial.

Weinstock MA, Bingham SF, Digiovanna JJ, Rizzo AE, Marcolivio K, Hall R, Eilers D, Naylor M, Kirsner R, Kalivas J, Cole G, Vertrees JE; Veterans Affairs Topical Tretinoin Chemoprevention Trial Group.

J Invest Dermatol. 2012 Jun;132(6):1583-90. doi: 10.1038/jid.2011.483. Epub 2012 Feb 9.

13.

Association between non-steroidal anti-inflammatory drugs and keratinocyte carcinomas of the skin among participants in the Veterans Affairs Topical Tretinoin Chemoprevention Trial.

Nunes AP, Lapane KL, Weinstock MA; VATTC Trial Group.

Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):922-9. doi: 10.1002/pds.2142. Epub 2011 Jun 18.

PMID:
21688346
14.

Prospective quality of life impact of keratinocyte carcinomas: observations from the Veterans Affairs Topical Tretinoin Chemoprevention Trial.

Lee KC, Weinstock MA; Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Trial Group.

J Am Acad Dermatol. 2010 Dec;63(6):1107-9. doi: 10.1016/j.jaad.2010.02.014. No abstract available.

PMID:
21093671
15.

Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.

Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks WJ Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ; CSP 468 Study Group.

N Engl J Med. 2010 Jun 3;362(22):2077-91. doi: 10.1056/NEJMoa0907083.

16.

Tolerability of high-dose topical tretinoin: the Veterans Affairs Topical Tretinoin Chemoprevention Trial.

Geng A, Weinstock MA, Hall R, Eilers D, Naylor M, Kalivas J; VATTC Trial Group.

Br J Dermatol. 2009 Oct;161(4):918-24. doi: 10.1111/j.1365-2133.2009.09341.x. Epub 2009 Jun 11.

PMID:
19681859
17.

Quality of life in the actinic neoplasia syndrome: The VA Topical Tretinoin Chemoprevention (VATTC) Trial.

Weinstock MA, Lee KC, Chren MM, Marcolivio K; VATTC Trial Group.

J Am Acad Dermatol. 2009 Aug;61(2):207-15. doi: 10.1016/j.jaad.2009.02.022. Epub 2009 Apr 26.

18.

Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial.

Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF; Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group.

Cancer. 2009 Jun 1;115(11):2523-30. doi: 10.1002/cncr.24284.

19.

Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial.

Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, Rothlind J, Sagher O, Reda D, Moy CS, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein J, Stoner G, Heemskerk J, Huang GD; CSP 468 Study Group.

JAMA. 2009 Jan 7;301(1):63-73. doi: 10.1001/jama.2008.929.

20.

Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.

Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA; VATTC Trial.

J Natl Cancer Inst. 2008 Sep 3;100(17):1223-32. doi: 10.1093/jnci/djn262. Epub 2008 Aug 26.

PMID:
18728281

Supplemental Content

Loading ...
Support Center